Unknown

Dataset Information

0

A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.


ABSTRACT: Research efforts on the human immunodeficiency virus (HIV) integrase have resulted in two approved drugs. However, co-infection of HIV with Mycobacterium tuberculosis and other microbial and viral agents has introduced added complications to this pandemic, requiring favorable drug-drug interaction profiles for antiviral therapeutics targeting HIV. Cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) are pivotal determining factors in the occurrence of adverse drug-drug interactions. For this reason, it is important that anti-HIV agents, such as integrase inhibitors, possess favorable profiles with respect to CYP and UGT. We have discovered a novel HIV integrase inhibitor (compound 1) that exhibits low nM antiviral activity against a diverse set of HIV-1 isolates, and against HIV-2 and the simian immunodeficiency virus (SIV). Compound 1 displays low in vitro cytotoxicity and its resistance and related drug susceptibility profiles are favorable. Data from in vitro studies revealed that compound 1 was not a substrate for UGT isoforms and that it was not an inhibitor or activator of key CYP isozymes.

SUBMITTER: Okello MO 

PROVIDER: S-EPMC3677213 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.

Okello Maurice O MO   Mishra Sanjay S   Nishonov Malik M   Mankowski Marie K MK   Russell Julie D JD   Wei Jiayi J   Hogan Priscilla A PA   Ptak Roger G RG   Nair Vasu V  

Antiviral research 20130418 3


Research efforts on the human immunodeficiency virus (HIV) integrase have resulted in two approved drugs. However, co-infection of HIV with Mycobacterium tuberculosis and other microbial and viral agents has introduced added complications to this pandemic, requiring favorable drug-drug interaction profiles for antiviral therapeutics targeting HIV. Cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) are pivotal determining factors in the occurrence of adverse drug-drug in  ...[more]

Similar Datasets

| S-EPMC4384416 | biostudies-literature
| S-EPMC2819755 | biostudies-literature
| S-EPMC10322778 | biostudies-literature
| S-EPMC2949660 | biostudies-literature
| PRJEB38781 | ENA
| S-EPMC4205369 | biostudies-literature
| S-EPMC4851305 | biostudies-literature
| S-EPMC3927478 | biostudies-literature
| S-EPMC5995049 | biostudies-literature
| S-EPMC7042106 | biostudies-literature